IL198344A0 - Use of mtki 1 for treating or preventing bone cancer - Google Patents

Use of mtki 1 for treating or preventing bone cancer

Info

Publication number
IL198344A0
IL198344A0 IL198344A IL19834409A IL198344A0 IL 198344 A0 IL198344 A0 IL 198344A0 IL 198344 A IL198344 A IL 198344A IL 19834409 A IL19834409 A IL 19834409A IL 198344 A0 IL198344 A0 IL 198344A0
Authority
IL
Israel
Prior art keywords
mtki
treating
bone cancer
preventing bone
preventing
Prior art date
Application number
IL198344A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL198344A0 publication Critical patent/IL198344A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL198344A 2006-10-27 2009-04-23 Use of mtki 1 for treating or preventing bone cancer IL198344A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86316706P 2006-10-27 2006-10-27
EP06123060 2006-10-27
US97618807P 2007-09-28 2007-09-28
PCT/EP2007/061501 WO2008049904A2 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Publications (1)

Publication Number Publication Date
IL198344A0 true IL198344A0 (en) 2010-02-17

Family

ID=39066650

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198344A IL198344A0 (en) 2006-10-27 2009-04-23 Use of mtki 1 for treating or preventing bone cancer

Country Status (11)

Country Link
EP (1) EP2101782A2 (ja)
JP (1) JP2010507628A (ja)
KR (1) KR20090086977A (ja)
AU (1) AU2007310845A1 (ja)
BR (1) BRPI0718021A2 (ja)
CA (1) CA2664165A1 (ja)
EA (1) EA200970420A1 (ja)
IL (1) IL198344A0 (ja)
MX (1) MX2009004438A (ja)
NO (1) NO20092059L (ja)
WO (1) WO2008049904A2 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8603801A1 (es) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
NO20092059L (no) 2009-06-29
MX2009004438A (es) 2009-05-11
KR20090086977A (ko) 2009-08-14
JP2010507628A (ja) 2010-03-11
EA200970420A1 (ru) 2009-12-30
EP2101782A2 (en) 2009-09-23
AU2007310845A1 (en) 2008-05-02
BRPI0718021A2 (pt) 2013-11-12
WO2008049904A2 (en) 2008-05-02
CA2664165A1 (en) 2008-05-02
WO2008049904A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
IL248204A0 (en) Combined treatment of tumors expressing 38cd
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
HK1125868A1 (en) Compositions and methods for treating bone
EP2125855A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
PT2529626T (pt) Composições e métodos para tratamento ou prevenção do cancro do cólon
IL188430A0 (en) Treatment of tumors
ZA200708575B (en) Methods and compositions for treating or preventing cancer
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL243294A0 (en) Compounds and compositions for the treatment of cancer
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
HK1117780A1 (en) Compounds and methods for the treatment of cancer
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1904088A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
IL226363A0 (en) Compounds and methods for treating cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
HK1225304A1 (zh) 治療骨癌
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer